Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03407651 | Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B | PHASE2 | COMPLETED | 11 | — | — | Dec 1, 2017 | Apr 1, 2019 | Sep 22, 2021 | - | — |
| Name | Type | Description |
|---|---|---|
| Coagulation Factor VIIa variant | BIOLOGICAL | Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required. |